Your shopping cart is currently empty

VI-60 is an orally active dual inhibitor of cPLA2 and COX-2, exhibiting anti-inflammatory properties by suppressing the p38 MAPK/cPLA2/COX-2/PGE2 pathway.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | VI-60 is an orally active dual inhibitor of cPLA2 and COX-2, exhibiting anti-inflammatory properties by suppressing the p38 MAPK/cPLA2/COX-2/PGE2 pathway. |
| In vitro | VI-60 (10 μM, 24-48 h) suppresses the production of LPS-induced inflammatory mediators NO (with an IC50 of 3.85 μM) and PGE2, without showing significant cytotoxicity in RAW264.7 cells. |
| In vivo | VI-60 (20 mg/kg, administered orally, daily or every other day) alleviates adjuvant-induced arthritis and exhibits analgesic effects in Lewis rats. When given daily at the same dose, VI-60 modulates the balance of Th17 and Tregs by inhibiting the p38 MAPK/cPLA2/COX-2/PGE2 pathway and reduces IL-17 expression. In Wistar rats, VI-60 presents a low probability of ulceration at 50 mg/kg and shows no hepatotoxicity or nephrotoxicity at a dose of 20 mg/kg administered orally. |
| Formula | C37H43F3O3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.